Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
501-520 of 653 trials

Neovascular Age-Related Macular Degeneration: Port Delivery System with Ranibizumab

We are studying a new delivery system for ranibizumab in patients with neovascular age-related macular degeneration. The goal is to see how well it works and how it affects patients' treatment experiences.

Neovascular Age-Related Macular Degeneration1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology

Monalizumab for Acute Myeloid Leukemia and Myelodysplastic Syndrome

We are studying the safety and effectiveness of Monalizumab in patients with acute myeloid leukemia or myelodysplastic syndrome receiving a stem cell transplant. This trial aims to understand its impact on recovery and survival.

Acute Myeloid Leukemia1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Systemic Sclerosis: Nintedanib and Tocilizumab Study

We are testing a combination of nintedanib and tocilizumab for patients with systemic sclerosis and interstitial lung disease. The goal is to see if this new treatment is more effective than standard therapies.

Systemic SclerosisSystemic Sclerosis with Interstitial Lung Disease1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPulmonologyRheumatology

Crohn's Disease: SAR442970 Study

We are investigating the effects of a new medication, SAR442970, on adults with moderate to severe Crohn's disease. The study aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Golcadomide for Brain Lymphoma: A Phase 2 Study

We are studying the effectiveness of golcadomide in patients with relapsed or refractory large B-cell lymphoma in the brain. The goal is to see if it can help achieve remission and improve overall health.

Diffuse Large B-Cell LymphomaSecondary Central Nervous System LymphomaRelapsed Primary Large B-Cell Lymphoma of the Central Nervous System1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Cutaneous Melanoma: IMA203 Treatment Study

We are comparing a new treatment called IMA203 with the best available options for patients with advanced skin cancer. This study aims to see if IMA203 is more effective and safe for those who have already been treated.

Skin Melanoma1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Antibiotics in Bile Fluid: A Study for Patients with Biliary Drainage

We are investigating how antibiotics are processed in the bile of patients with external biliary drainage. This research may help improve treatment strategies for these patients.

Cholangitis1-2 yearsSafety phase (I)GastroenterologyHepatology

Chronic Hepatitis Delta: BJT-778 vs Bulevirtide

We are studying a new treatment called brelovitug for chronic hepatitis delta infection to see if it works better and is safer than the current treatment, bulevirtide. We also want to understand how it affects patients' quality of life.

Chronic Hepatitis D Infection1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Multiple System Atrophy: Lu AF82422 Study

We are testing the medication Lu AF82422 to see if it can slow disease progression in people with Multiple System Atrophy. The study will also look at its effects on overall health and quality of life.

Multiple System Atrophy1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Schizophrenia Treatment: Cannabidiol vs. Placebo

We are studying whether adding cannabidiol to standard antipsychotic treatment helps improve recovery in early schizophrenia. The trial will also look at safety and changes in mental and social functioning.

Remitted Schizophrenia1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry

Advanced Lung Cancer: Atezolizumab vs. Atezolizumab Plus Bevacizumab

We are studying whether adding bevacizumab to atezolizumab helps patients with advanced non-small-cell lung cancer live longer than using atezolizumab alone. This trial is for those with high PD-L1 expression who have not yet received treatment.

Advanced Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Alzheimer’s Disease: Dimethyl Fumarate Study

We are investigating whether dimethyl fumarate can improve memory and daily activities in patients with mild cognitive impairment and Alzheimer's disease. This study will also assess its effects on brain health and quality of life.

Alzheimer's Disease1-2 yearsEfficacy phase (II)Standard MedicinesNeurologyPsychiatry

Juvenile Psoriatic Arthritis: Deucravacitinib Study

We are testing a new medication, deucravacitinib, in children and teens aged 5 to 18 with Juvenile Psoriatic Arthritis. The study aims to see if it works better than a placebo and to ensure it is safe and easy to take.

Systemic Juvenile Idiopathic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsRheumatology

T-Guard for Early Diffuse Cutaneous Systemic Sclerosis

We are studying the safety and effectiveness of T-Guard in patients with early diffuse cutaneous systemic sclerosis. This trial will help us understand how well the treatment works and how it is processed in the body.

Diffuse Systemic Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyInternal MedicineRheumatology

Psoriatic Arthritis: JNJ-77242113 Study

We are testing a new medication for people with active psoriatic arthritis who have used other biologic treatments. The study aims to see if it can reduce symptoms better than a placebo.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Hydrocortisone Absorption: Oral vs. Oral Mucosa

We are comparing how well hydrocortisone is absorbed from dissolvable films in healthy volunteers and adults with adrenal insufficiency. This study aims to find the most effective way to deliver this important medication.

Adrenal Insufficiency1-2 yearsSafety phase (I)Endocrinology

IVF/ICSI: Optimizing Recombinant FSH Dosing

We are studying the best dose of recombinant FSH for patients undergoing IVF/ICSI to improve hormone levels and pregnancy outcomes. This research may help enhance fertility treatment success.

Female Subfertility1-2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Dental Implants: Antibiotic Use in Bone Augmentation

We are studying whether short or long-term antibiotic use is more effective during dental implant surgery. This trial will also look at how these antibiotics affect bacteria in the mouth and gut.

Need for Oral Bone Augmentation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Improving Ovarian Reserve: rhLH Treatment Study

We are investigating whether a hormone treatment can increase the number of healthy follicles in women trying to conceive. This study aims to assess its effects on fertility and overall safety.

Assisted Fertilization1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Intranasal Lysine-Aspirin for Respiratory Disease

We are studying the effects of a new nasal treatment on asthma and nasal symptoms in patients with NSAID-exacerbated respiratory disease. The goal is to see if it improves breathing and overall quality of life.

Nonsteroidal Anti-Inflammatory Drug Exacerbated Respiratory Disease (N-ERD)1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology